These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27639220)

  • 21. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
    Tshiani Mbaya O; Mukumbayi P; Mulangu S
    Front Immunol; 2021; 12():721328. PubMed ID: 34526994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups.
    Dodd LE; Follmann D; Proschan M; Wang J; Malvy D; van Griensven J; Ciglenecki I; Horby PW; Ansumana R; Jiang JF; Davey RT; Lane HC; Gouel-Cheron A
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary Anti-Ebola Drug Discovery Approaches and Platforms.
    Schneider-Futschik EK; Hoyer D; Khromykh AA; Baell JB; Marsh GA; Baker MA; Li J; Velkov T
    ACS Infect Dis; 2019 Jan; 5(1):35-48. PubMed ID: 30516045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Against the clock towards new Ebola virus therapies.
    Martínez-Romero C; García-Sastre A
    Virus Res; 2015 Nov; 209():4-10. PubMed ID: 26057711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of experimental and early investigational drugs for the treatment of Ebola virus infections.
    Wong G; Qiu X
    Expert Opin Investig Drugs; 2015; 24(8):999-1011. PubMed ID: 26065319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp.
    Wong G; Bienes KM; Xiii A; Fausther-Bovendo H; Kobinger GP
    Antiviral Res; 2024 Jun; 226():105873. PubMed ID: 38580170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Ebola Virus Disease: The Largest Ever Recorded Outbreak in West Africa].
    Kato Y
    Nihon Naika Gakkai Zasshi; 2016 Sep; 105(9):1803-8. PubMed ID: 30170343
    [No Abstract]   [Full Text] [Related]  

  • 28. Stakeholders' engagement with Ebola therapy research in resource limited settings.
    Folayan MO; Brown B; Haire B; Yakubu A; Peterson K; Tegli J
    BMC Infect Dis; 2015 Jun; 15():242. PubMed ID: 26113124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020.
    Mulangu S; Mbala-Kingebeni P; Mbaya OT
    N Engl J Med; 2022 Mar; 386(12):1188-1191. PubMed ID: 35320651
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.
    Kroeker A; Griffin BD; Qiu X; Kobinger G
    Methods Mol Biol; 2017; 1628():273-282. PubMed ID: 28573628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ebola virus disease and the veterinary perspective.
    Gumusova S; Sunbul M; Leblebicioglu H
    Ann Clin Microbiol Antimicrob; 2015 May; 14():30. PubMed ID: 26018030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease.
    Schafer A; Cheng H; Lee C; Du R; Han J; Perez J; Peet N; Manicassamy B; Rong L
    Curr Med Chem; 2018; 25(38):5177-5190. PubMed ID: 29032747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibuprofen as a template molecule for drug design against Ebola virus.
    Paessler S; Huang C; Sencanski M; Veljkovic N; Perovic V; Glisic S; Veljkovic V
    Front Biosci (Landmark Ed); 2018 Jan; 23(5):947-953. PubMed ID: 28930583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethics of Conducting Clinical Research in an Outbreak Setting.
    Edwards KM; Kochhar S
    Annu Rev Virol; 2020 Sep; 7(1):475-494. PubMed ID: 32212920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling Ebola virus dynamics: Implications for therapy.
    Martyushev A; Nakaoka S; Sato K; Noda T; Iwami S
    Antiviral Res; 2016 Nov; 135():62-73. PubMed ID: 27743917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola.
    Cavaleri M; Thomson A; Salmonson T; Hemmings RJ
    Clin Trials; 2016 Feb; 13(1):101-4. PubMed ID: 26768561
    [No Abstract]   [Full Text] [Related]  

  • 37. The 2014 Ebola virus outbreak in West Africa highlights no evidence of rapid evolution or adaptation to humans.
    Li X; Zai J; Liu H; Feng Y; Li F; Wei J; Zou S; Yuan Z; Shao Y
    Sci Rep; 2016 Oct; 6():35822. PubMed ID: 27767073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.
    Bausch DG; Sprecher AG; Jeffs B; Boumandouki P
    Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New rules needed to stop the Ebola epidemic.
    Hasle G
    Tidsskr Nor Laegeforen; 2014 Oct; 134(19):1826-7. PubMed ID: 25314981
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of Small-Molecule Antivirals for Ebola.
    Janeba Z
    Med Res Rev; 2015 Nov; 35(6):1175-94. PubMed ID: 26172225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.